Teva Executive and Leadership Team

Marija Bubanja, the Chief Financial Officer at Teva, directs global financial strategy and operations. Overseeing all fiscal activities, Bubanja ensures robust financial planning and analysis to support Teva's mission of improving health outcomes worldwide. This leadership role involves managing budgets, forecasting revenue, and optimizing resource allocation across the organization. By driving financial discipline, Marija Bubanja directly contributes to the company's ability to deliver a broad portfolio of medicines, including complex generics and innovative therapies. The Chief Financial Officer's oversight extends to risk management and ensuring compliance with international financial regulations, thereby safeguarding Teva's market position and long-term sustainability. This executive ensures financial health supports the advancement of scientific research and expanded access to quality medicines.

Alexander Joramsa, the Chief Financial Officer (Asia Pacific, Japan) at Teva, spearheads financial operations across key Asian and Japanese markets. Joramsa manages regional financial planning, reporting, and compliance, ensuring alignment with Teva's global strategic objectives. This role is critical for supporting the development, manufacturing, and delivery of Teva's diverse medicine portfolio within these dynamic territories. By optimizing financial strategies, Alexander Joramsa facilitates market expansion and enhances access to essential treatments. The Chief Financial Officer's focus includes driving revenue growth and cost efficiency across the Asia Pacific and Japan regions. Joramsa's leadership ensures that financial frameworks effectively support Teva's commitment to addressing unmet patient needs through scientific research and accessible pharmaceutical solutions.

Dov Primovitch, the Chief Financial Officer (Israel) at Teva, leads all financial functions within the company's home market. Primovitch oversees financial planning, accounting, and treasury operations, ensuring fiscal integrity and strategic resource deployment. This position is vital for supporting Teva's extensive operations in Israel, from manufacturing to research and development. By driving financial efficiency, Dov Primovitch contributes directly to the company's ability to deliver a broad range of medicines, including complex generics and innovative therapies. The Chief Financial Officer's responsibilities include managing local financial compliance and optimizing profitability within the Israeli landscape. Primovitch's financial acumen supports Teva's dedication to advancing scientific research and ensuring broad access to quality pharmaceutical products.

Craig Olson, the Chief Financial Officer, Operations at Teva, directs financial strategy and oversight for the company's global manufacturing and supply chain operations. Olson ensures operational efficiency and cost-effectiveness across Teva's production facilities worldwide. This critical role involves managing operational budgets, capital expenditures, and financial performance metrics to support the reliable delivery of medicines. By optimizing financial processes within operations, Craig Olson directly enhances Teva's capacity to provide complex generics, biosimilars, and innovative therapies to patients globally. The Chief Financial Officer's focus includes driving continuous improvement in financial management to streamline the delivery of treatments. Olson's leadership ensures that operational finances robustly support Teva's mission of improving health outcomes and expanding access to essential medicines.

Eli Kalif, the Chief Financial Officer & Executive VP at Teva, holds comprehensive responsibility for the company's global financial strategy and execution. Kalif oversees all aspects of financial management, including accounting, treasury, investor relations, and financial planning, ensuring robust fiscal health across Teva's worldwide operations. This executive leadership position is fundamental to supporting Teva's mission of improving health outcomes by enabling the development, manufacturing, and delivery of a broad portfolio of medicines. By driving financial discipline and strategic investment, Eli Kalif directly contributes to advancing scientific research and expanding access to quality treatments. The Chief Financial Officer's oversight ensures financial resources are optimally allocated to address unmet patient needs and foster innovation, solidifying Teva's position as a global biopharmaceutical leader.

Yehuda Koren, the Director, Financial & Chief Financial Officer, S L E at Teva, manages financial operations and strategy for specific business segments. Koren oversees financial planning, analysis, and reporting, ensuring fiscal accountability and supporting strategic decision-making within the designated areas. This role is crucial for optimizing the financial performance of Teva's specialized product lines and therapeutic solutions. By implementing effective financial controls and driving efficiency, Yehuda Koren contributes to Teva's capacity to deliver a diverse range of medicines. The Director, Financial & Chief Financial Officer's focus includes managing budgets and resource allocation to support research and development initiatives. Koren's financial leadership ensures that these segments align with Teva's broader mission of improving patient health outcomes.

Luigi Tiravanti, the Director, Finance & Chief Financial Officer at Teva, directs financial strategy and operations for key divisions. Tiravanti oversees budgeting, forecasting, and financial reporting, ensuring fiscal responsibility and supporting strategic growth objectives. This position is essential for managing the financial health of specific business units and contributing to Teva's overall mission of improving global health outcomes. By driving financial efficiency and providing critical insights, Luigi Tiravanti supports the development and delivery of a broad portfolio of medicines. The Director, Finance & Chief Financial Officer's responsibilities include optimizing resource allocation and ensuring compliance with financial regulations. Tiravanti's financial acumen strengthens Teva's commitment to advancing scientific research and expanding access to quality treatments.

Guillermo Monroy, the LATAM Corporate Development Chief of Staff & Director (Mergers Acquisitions & Strategy) at Teva, drives strategic growth initiatives across Latin America. Monroy leads merger, acquisition, and divestiture activities, identifying and executing opportunities that align with Teva's global biopharmaceutical objectives. This role is pivotal in expanding Teva's market presence and portfolio within the LATAM region. By architecting strategic partnerships and acquisitions, Guillermo Monroy enhances Teva's ability to deliver a broad spectrum of medicines, including innovative therapies tailored to regional needs. The Chief of Staff's responsibilities include ensuring seamless integration of acquired entities and optimizing strategic planning processes. Monroy's expertise in corporate development directly supports Teva's mission to improve health outcomes and advance scientific research.

Hagay Leibowitz, the Chief Marketing Officer, Project & Tgo, Teva Leader at Teva, drives marketing strategy and execution for key projects and initiatives. Leibowitz oversees market analysis, brand development, and go-to-market strategies, ensuring Teva's medicines reach patients effectively. This leadership role is critical for communicating the value of Teva's broad portfolio, including complex generics and innovative therapies, to healthcare professionals and consumers. By shaping compelling marketing campaigns, Hagay Leibowitz enhances market penetration and supports Teva's mission to improve health outcomes. The Chief Marketing Officer's focus includes leading cross-functional teams to achieve commercial success and expand access to quality treatments. Leibowitz's strategic marketing leadership directly contributes to advancing scientific research and addressing unmet patient needs.

Martin Laughlin, the Chief of Staff and Head of Commercial Excellence at Teva, enhances operational efficiency and drives strategic commercial initiatives. Laughlin oversees the implementation of best practices across sales and marketing functions, ensuring alignment with Teva's global business objectives. This role is vital for optimizing commercial performance and supporting the delivery of Teva's diverse medicine portfolio. By fostering commercial excellence, Martin Laughlin contributes to expanding access to quality treatments and improving patient health outcomes. The Chief of Staff's responsibilities include streamlining internal processes and driving strategic projects that support Teva's mission. Laughlin's leadership ensures that commercial operations are highly effective in reaching patients with essential pharmaceutical solutions.